Physician profile
Shashi A Kumar
NPI 1083619225
$8,374.64
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $1,267 · 2021: $1,363 · 2022: $1,533 · 2023: $1,524 · 2024: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.44 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,760.91 | 2019-2024 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,397.17 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,076.68 | 2019-2024 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $761.79 | 2020-2024 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $578.67 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $510.05 | 2019-2024 | |
| Genzyme Corporation | $443.06 | 2019-2024 | |
| Optinose US, INC. | $415.28 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $359.78 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $264.34 | 2021-2024 | Xembify |
| Kaleo, INC. | $181.77 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $145.98 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.13 | 2020-2022 | |
| Alkermes, INC. | $71.91 | 2023 | Lybalvi |
| Hikma Pharmaceuticals USA | $64.81 | 2023-2024 | Ryaltris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $47.71 | 2020-2021 | |
| Shire North American Group INC | $42.73 | 2019 | |
| Amgen INC. | $30.44 | 2024 | Tezspire |
| Jubilant Hollisterstier LLC | $23.88 | 2020 | |
| Leo Pharma INC. | $21.96 | 2022 | |
| Blueprint Medicines Corporation | $20.42 | 2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $15.67 | 2019 | |
| Pfizer INC. | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.